LAGOS, NIGERIA — Professor Mojisola Adeyeye, Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), has attributed the counterfeit medicine crisis in Nigeria to decades of structural weaknesses in the nation’s pharmaceutical regulatory system, uncontrolled open drug markets, and infiltration by unqualified traders.
Regulatory lapses in managing patent medicine vendors allowed untrained individuals to dominate informal distribution channels when oversight responsibility shifted between regulatory bodies. “The country is flooded with people that don’t understand anything about medicine,” Ms. Adeyeye noted, highlighting how supply chain vulnerabilities threaten public health safety.
Supply Chain Dependencies and Operational Vulnerabilities
Structural dependency on foreign markets creates multiple points of entry for substandard and falsified medical products:
Risk Category
Structural Percentage
Supply Chain Impact
Finished Medicine Imports
Over 70%
High exposure to foreign currency and trade fluctuations
Raw Material Imports
96%
Local manufacturing heavily dependent on foreign suppliers
Open Market Penetration
Uncontrolled
Informal urban and rural vendors operating without oversight
How NAFDAC Tackles The Counterfeit Medicine Crisis In Nigeria
To mitigate these risks, NAFDAC is standardizing its registration process using the Common Technical Document format to align with international best practices. Between May and July 2026, targeted enforcement operations successfully removed 7,210 counterfeit or substandard products from circulation.
The agency is also deploying pharmacist volunteer networks into local communities to extend regulatory oversight into open markets. Addressing the counterfeit medicine crisis in Nigeria requires independent oversight, as Ms. Adeyeye emphasized: “The moment a regulator can be bought, the public loses its only protection.”
In parallel, Nigeria’s accession to the African Medicines Agency aims to streamline cross-border regulatory coordination and secure essential supply chains across West Africa.
Why It Matters: Combatting counterfeit medicine distribution requires structural regulatory reform, supply chain transparency, and sustained public health enforcement across West Africa.
NAFDAC's Plan to Review Sanctions on Exporters of… The National Agency for Food and Drug Administration and Control (NAFDAC) has announced its intention to review the sanctions imposed on exporters of substandard products [1]. This decision comes in response to the increasing rejection of…
Counterfeit Medicine Crisis Rooted in Regulatory Gaps LAGOS, NIGERIA — Professor Mojisola Adeyeye, Director-General of NAFDAC, has linked the counterfeit medicine crisis in Nigeria to three decades of institutional regulatory gaps. Speaking on September 9, 2026, Adeyeye outlined how historical oversights in…
NAFDAC Issues Public Alert Regarding Circulation of… The National Agency for Food and Drugs Administration and Control (NAFDAC) has raised a red flag concerning the presence of counterfeit Meronem 1g Injection in circulation in Nigeria. This alert, detailed in a public notice…
NAFDAC Issues Strong Warning Against Consuming… National Agency for Food and Drugs Administration and Control (NAFDAC) Cautions Nigerians on the Dangers of Chemically Ripened Fruits In a stern warning to the public, the National Agency for Food and Drugs Administration and…
